Topical rVA576 for Treatment of Atopic Keratoconjunctivitis

Exclusion Criteria

• •1. Eye surface disease other than AKC, VKC or severe allergic conjunctivitis (SAC or PAC)
• •2. Contact lens use during the study
• •3. Complete or partial tarsorrhaphy. If such a procedure becomes necessary during the course of the trial patients may remain in the trial providing that at least 50% of the eye surface remains visible to slit lamp examination
• •4. Ankyloblepharon of any degree at entry to the trial
• •5. Known or suspected ocular malignancy
• •6. Active ocular infection at entry to the trial. Patients with eye surface bacterial, viral, fungal or protozoal infection may enter the trial after elimination of the infection as confirmed by eye swabs
• •7. Known or suspected uveitis
• •8. Participation in any other clinical trial within 1 month of enrolment
• •9. Use of any of the following prohibited medications:
• •* Eculizumab
• •* Any other investigational complement inhibitor whether systemic or topical (e.g. RA101495)
• •* Montelukast
• •* Zafirlukast
• •* Pranlukast
• •* Zileuton
• •* Hypericum perforatum (St John's wort)
• •10. Corneal perforation
• •11. Uncontrolled glaucoma (increase in dose of glaucoma medication or surgical intervention for glaucoma within 3 months prior to entry)
• •12. Pregnancy (females)
• •13. Breast feeding (females)
• •14. Known allergy to ticks or severe reaction to arthropod venom (e.g. bee or wasp venom)
• •15. Use of topical ocular steroids within 7 days of the Screening visit
• •16. Failure to satisfy the PI of suitability to participate for any other reason